

MATTERS ARISING

Open Access



# Reply to: angiotensinogen: a new era beyond lactate as a biomarker?

Mark C. Chappell<sup>1\*</sup>, Christopher L. Schaich<sup>1</sup> and Ashish K. Khanna<sup>1,2,3</sup>

Dear Editor,

We appreciate the comments from Drs. Shen and Ding [1] regarding our brief research report, “*Stronger association of intact angiotensinogen with mortality than lactate or renin in critical illness: post-hoc analysis from the VICTAS trial*” [2]. Their letter addresses several excellent points about the extent and severity of septic shock in the VICTAS cohort in relation to serum lactate. We agree that the serum levels of lactate were not excessively elevated in our patient population which likely reflects the fact that most of the VICTAS patients were not in severe septic shock. Nonetheless, there was significant mortality in this cohort of sepsis patients that was strongly associated with circulating levels of intact angiotensinogen, suggesting under these conditions that intact angiotensinogen as a biomarker outperformed both renin and lactate according to model performance metrics including area under the curve and the Youden index. Thus, we believe intact angiotensinogen may constitute an additional clinical tool in the care of patients in early sepsis or septic shock. We previously showed that active renin

also associated with mortality in this cohort consistent with the recent literature that renin may be a predictor of disease severity that outperforms lactate, as well as a potential indicator for exogenous Ang II treatment to maintain blood pressure and tissue perfusion [3–5]. As renin converts angiotensinogen to Ang I and then Ang II through ACE, our results suggest that reduced levels of intact angiotensinogen through excessive renin activity and/or impaired synthesis may also be an indicator of disease severity and may further reveal the need for exogenous Ang II therapy in sepsis patients. The accurate and rapid assessment of plasma Ang II levels is not currently feasible, whereas assay of intact angiotensinogen and active renin or their combination may be a more suitable point-of-care test for critical care patients [2]. We also agree that additional time points in the course of disease are necessary in the assessment of angiotensinogen and other components of the renin–angiotensin–aldosterone system (RAAS) in the critically ill, as well as more detailed assessment of optimal clinical thresholds for each. Indeed, a clinical trial in septic shock patients that directly arose from our present study is currently under way at Wake Forest University School of Medicine that is designed to address several of the issues raised by Drs. Shen and Ding regarding the response of the circulating RAAS and serum lactate.

This comment refers to the article available online at <https://doi.org/10.1186/s13054-024-05120-w>.

This reply refers to the comment available online at <https://doi.org/10.1186/s13054-024-05164-y>.

\*Correspondence:

Mark C. Chappell  
mchappel@wakehealth.edu

<sup>1</sup> Hypertension Center, Wake Forest University School of Medicine, Winston-Salem, NC 27101, USA

<sup>2</sup> Department of Anesthesiology, Section On Critical Care Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA

<sup>3</sup> Outcomes Research Consortium, Cleveland, OH, USA

#### Acknowledgements

Not applicable.

#### Author contributions

M.C.C., C.L.S., and A.K.K., all prepared and wrote this manuscript text. All authors reviewed and approved this final manuscript.

#### Funding

None.



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

**Availability of data and materials**

No datasets were generated or analysed during the current study.

**Declarations****Ethics approval and consent to participate**

Not applicable.

**Consent for publication**

Not applicable.

Received: 14 November 2024 Accepted: 18 November 2024

Published online: 16 December 2024

**References**

1. Shen Y, Ding X. Angiotensinogen: a new era beyond lactate as a biomarker? *Crit Care*. 2024. <https://doi.org/10.1186/s13054-024-05164-y>.
2. Chappell MC, Schaich CL, Busse LW, Martin GS, Sevransky JE, Hinson JK, Khanna AK. Vitamin C TSiSI: stronger association of intact angiotensinogen with mortality than lactate or renin in critical illness: post-hoc analysis from the VICTAS trial. *Crit Care*. 2024;28(1):333. <https://doi.org/10.1186/s13054-024-05120-w>.
3. Busse LW, Schaich CL, Chappell MC, McCurdy MT, Staples EM, Ten Lohuis CC, et al. Association of active renin content with mortality in critically ill patients: a post hoc analysis of the vitamin c, thiamine, and steroids in sepsis (VICTAS) trial. *Crit Care Med*. 2024;52:441–51.
4. Weinberger J, Klompas M, Rhee C. What is the utility of measuring lactate levels in patients with sepsis and septic shock? *Semin Respir Crit Care Med*. 2021;42:650–61.
5. Jeyaraju M, McCurdy MT, Levine AR, Devarajan P, Mazzeffi MA, Mullins KE, et al. Renin kinetics are superior to lactate kinetics for predicting in-hospital mortality in hypotensive critically ill patients. *Crit Care Med*. 2022;50:50–60.

**Publisher's Note**

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.